Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Abstract

Acquired drug resistance is common during chemotherapy. Here, the authors describe the structural basis and molecular mechanism by which allosteric and clinically approved, ATP-competitive inhibitors of EGFR synergize to overcome resistance in lung cancer.